🇺🇸 FDA
Pipeline program

Ianalumab

CVAY736Q12202B

Phase 3 mab active

Quick answer

Ianalumab for Primary Immune Thrombocytopenia is a Phase 3 program (mab) at Novartis Pharmaceuticals with 2 ClinicalTrials.gov record(s).

Program details

Company
Novartis Pharmaceuticals
Indication
Primary Immune Thrombocytopenia
Phase
Phase 3
Modality
mab
Status
active

Clinical trials